- MBS Program Should be Extended: Fed's Bullard
- Wall Street Finds Profits by Reducing Mortgages
- Microsoft, News Corp Weigh Online News Pact
- Warren Buffett, Bill Gates 'Walk & Talk' At Columbia
- Senate Democrats at Odds Over Health Care Bill
- What if a Recovery Is All in Your Head?
- Thanksgiving Week Stuffed With Economic News
- 10 Tips to Get Out of Debt
- This Season: Everybody's A Scrooge
- U.S. Stocks Slip, Dollar Rises
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
- Holiday Tipping: Who And How Much
- Economic survey: Job losses to bottom out in 1Q
- Late payments on credit cards drop in 3rd quarter
- Singapore consumer prices fall for seventh month
- U.S.: Three Mile Island radiation not significant
- Report: Ill. prison deal could create 3,000 jobs
- Proposal to merge black schools draws fire
- Promoters have faith in ‘holy hip-hop’
- Real estate agents see return of foreign buyers
- Accounting rule helps boost some newspapers
Text Size 
NEW YORK - CVS Caremark Corp. said Tuesday it is planning to do more research on the interactions between a person's genes and the effectiveness of the drugs he or she is taking.
CVS said it is taking a minority stake in "genetic benefit management company" Generation Health Inc. It said the testing will help clients of the Caremark pharmacy benefits management business whose current medications are not working, or are causing unpleasant side effects.
Research on the interaction between genes and medication is called pharmacogenomics, and CVS is hoping it can use information from the testing to determine which drugs will work on which patients. If patients to begin their treatment with drugs that work rather than switching, that reduces medical costs.
Services from the partnership will be introduced to Caremark clients starting in the second quarter of 2010, and the partnership will focus on drugs for cancer, heart disease, HIV and other areas at first. The Woonsocket, R.I., company said it already does some pharmacogenomic testing in its specialty drug business, which focuses on dispensing drugs for chronic and complex illnesses such as diabetes.
Financial terms of the partnership between CVS and Generation Health were not disclosed. CVS Chief Medical Officer Troyen Brennan will join the board of Generation Health, which is based in Upper Saddle River, N.J.
In morning trading, CVS shares fell 48 cents to $30.42.
Print
Email
- Technology can make or break a fortune in the world of alternative energy.
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- Many people are facing the holidays with substantially smaller incomes. Here’s how some are adapting.
- Jim Cramer is a proponent of stocks that pay healthy dividends, and here are his top five dividend plays.
- The homebuyer's tax credit jacked sales for a while, but 2010 is looking weak. Now what?
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes